Back to Search Start Over

EP08.01-073 AdvanTIG-105: Phase 1b Dose-Expansion Study of Ociperlimab plus Tislelizumab in Patients with Metastatic NSCLC

Authors :
Kumar, R.
Kim, S.H.
Zhong, D.
Lu, S.
Cheng, Y.
Chen, M.
Cho, E.
Clay, T.
Kang, J.-H.
Lee, G.-W.
Sun, M.
Shim, B.-Y.
Spigel, D.R.
Yang, T.-Y.
Wang, Q.
Chang, G.-C.
Yu, G.
Wang, R.
Luo, X.
Zheng, H.
Gao, R.
Kim, H.R.
Source :
Journal of Thoracic Oncology; September 2022, Vol. 17 Issue: 9, Number 9 Supplement 1 pS375-S376, 2p
Publication Year :
2022

Details

Language :
English
ISSN :
15560864 and 15561380
Volume :
17
Issue :
9, Number 9 Supplement 1
Database :
Supplemental Index
Journal :
Journal of Thoracic Oncology
Publication Type :
Periodical
Accession number :
ejs62017199
Full Text :
https://doi.org/10.1016/j.jtho.2022.07.645